{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:09:13Z","timestamp":1790665753202,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:00:00Z","timestamp":1450396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the degeneration of spinal motor neurons. This disease is mainly caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. Currently, no effective treatment is available, and only symptomatic treatment can be provided. Our purpose in the present study was to establish a human SMA-derived induced pluripotent stem cell (SMA-iPSC) disease model and assay a therapeutic drug in preparation for the development of a novel treatment of SMA. We generated iPSCs from the skin fibroblasts of a patient with SMA and confirmed that they were pluripotent and undifferentiated. The neural differentiation of SMA-iPSCs shortened the dendrite and axon length and increased the apoptosis of the spinal motor neurons. In addition, we found activated astrocytes in differentiated SMA-iPSCs. Using this model, we confirmed that treatment with the thyrotropin-releasing hormone (TRH) analog, 5-oxo-l-prolyl-l-histidyl-l-prolinamide, which had marginal effects in clinical trials, increases the SMN protein level. This increase was mediated through the transcriptional activation of the SMN2 gene and inhibition of glycogen synthase kinase-3\u03b2 activity. Finally, the TRH analog treatment resulted in dendrite and axon development of spinal motor neurons in differentiated SMA-iPSCs. These results suggest that this human in vitro disease model stimulates SMA pathology and reveal the potential efficacy of TRH analog treatment for SMA. Therefore, we can screen novel therapeutic drugs such as TRH for SMA easily and effectively using the human SMA-iPSC model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Platelet-derived growth factor (PDGF) has recently been reported to produce the greatest increase in survival motor neuron protein levels by inhibiting glycogen synthase kinase (GSK)-3\u03b2; however, motor neurons lack PDGF receptors. A human in vitro spinal muscular atrophy-derived induced pluripotent stem cell model was established, which showed that the thyrotropin releasing hormone (TRH) analog promoted transcriptional activation of the SMN2 gene and inhibition of GSK-3\u03b2 activity, resulting in the increase and stabilization of the SMN protein and axon elongation of spinal motor neurons. These results reveal the potential efficacy of TRH analog treatment for SMA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5966\/sctm.2015-0059","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T05:41:11Z","timestamp":1450503671000},"page":"152-163","source":"Crossref","is-referenced-by-count":32,"title":["Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog"],"prefix":"10.1093","volume":"5","author":[{"given":"Kazuki","family":"Ohuchi","sequence":"first","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"},{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Funato","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichiro","family":"Kato","sequence":"additional","affiliation":[{"name":"United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ono","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nagahara","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Noda","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Kameyama","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"},{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Ando","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"},{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tsuruma","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Shimazawa","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hara","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,18]]},"reference":[{"key":"2021122704521290200_R1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol Dis"},{"key":"2021122704521290200_R2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0960-8966(97)00459-8","article-title":"Spinal muscular atrophy\u2014Clinical and genetic correlations","volume":"7","author":"Zerres","year":"1997","journal-title":"Neuromuscul Disord"},{"key":"2021122704521290200_R3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: A timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"key":"2021122704521290200_R4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2021122704521290200_R5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"2021122704521290200_R6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/4.10.1927","article-title":"Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: Evidence of homozygous deletions of the SMN gene in unaffected individuals","volume":"4","author":"Hahnen","year":"1995","journal-title":"Hum Mol Genet"},{"key":"2021122704521290200_R7","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122704521290200_R8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2021122704521290200_R9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.21832","article-title":"Insights into genotype-phenotype correlations in spinal muscular atrophy: A retrospective study of 103 patients","volume":"43","author":"Petit","year":"2011","journal-title":"Muscle Nerve"},{"key":"2021122704521290200_R10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ahg.12031","article-title":"Spinal muscular atrophy: From gene discovery to clinical trials","volume":"77","author":"Nurputra","year":"2013","journal-title":"Ann Hum Genet"},{"key":"2021122704521290200_R11","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122704521290200_R12","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2021122704521290200_R13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"J Clin Invest"},{"key":"2021122704521290200_R14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J Clin Invest"},{"key":"2021122704521290200_R15","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2021122704521290200_R16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"10","author":"Bowerman","year":"2012","journal-title":"BMC Med"},{"key":"2021122704521290200_R17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","article-title":"Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness","volume":"12","author":"Kondo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2021122704521290200_R18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13775","article-title":"Statin treatment rescues FGFR3 skeletal dysplasia phenotypes","volume":"513","author":"Yamashita","year":"2014","journal-title":"Nature"},{"key":"2021122704521290200_R19","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/0883073809333535","article-title":"Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy","volume":"24","author":"Kato","year":"2009","journal-title":"J Child Neurol"},{"key":"2021122704521290200_R20","doi-asserted-by":"crossref","first-page":"104535","DOI":"10.1155\/2014\/104535","article-title":"3D human motion editing and synthesis: A survey","volume":"2014","author":"Wang","year":"2014","journal-title":"Comput Math Methods Med"},{"key":"2021122704521290200_R21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nn1402","article-title":"Directed differentiation of telencephalic precursors from embryonic stem cells","volume":"8","author":"Watanabe","year":"2005","journal-title":"Nat Neurosci"},{"key":"2021122704521290200_R22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"key":"2021122704521290200_R23","doi-asserted-by":"crossref","first-page":"e39113","DOI":"10.1371\/journal.pone.0039113","article-title":"Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy","volume":"7","author":"Sareen","year":"2012","journal-title":"PLoS One"},{"key":"2021122704521290200_R24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","article-title":"A more efficient method to generate integration-free human iPS cells","volume":"8","author":"Okita","year":"2011","journal-title":"Nat Methods"},{"key":"2021122704521290200_R25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"2021122704521290200_R26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.stemcr.2015.02.010","article-title":"Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs","volume":"4","author":"Yoshida","year":"2015","journal-title":"Stem Cell Rep"},{"key":"2021122704521290200_R27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3233\/JAD-2004-6510","article-title":"Thyrotropin releasing hormone inhibits tau phosphorylation by dual signaling pathways in hippocampal neurons","volume":"6","author":"Luo","year":"2004","journal-title":"J Alzheimers Dis"},{"key":"2021122704521290200_R28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nchembio.595","article-title":"A screen for regulators of survival of motor neuron protein levels","volume":"7","author":"Makhortova","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2021122704521290200_R29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cbic.200400099","article-title":"Structure-aided optimization of kinase inhibitors derived from alsterpaullone","volume":"6","author":"Kunick","year":"2005","journal-title":"ChemBioChem"},{"key":"2021122704521290200_R30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00429-014-0743-7","article-title":"SMN is required for the maintenance of embryonic stem cells and neuronal differentiation in mice","volume":"220","author":"Chang","year":"2015","journal-title":"Brain Struct Funct"},{"key":"2021122704521290200_R31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/cr.2012.166","article-title":"Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res"},{"key":"2021122704521290200_R32","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/glia.22522","article-title":"Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production","volume":"61","author":"McGivern","year":"2013","journal-title":"Glia"},{"key":"2021122704521290200_R33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"2021122704521290200_R34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198201213060305","article-title":"Thyrotropin-releasing hormone","volume":"306","author":"Jackson","year":"1982","journal-title":"N Engl J Med"},{"key":"2021122704521290200_R35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1476-5381.1991.tb12179.x","article-title":"Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis","volume":"102","author":"Giovannini","year":"1991","journal-title":"Br J Pharmacol"},{"key":"2021122704521290200_R36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0304-3940(88)90123-1","article-title":"Contribution of cholinergic vasodilators on the increase in cerebral cortical blood flow responses to the intravenous administration of thyrotropin releasing hormone in anesthetized rats","volume":"88","author":"Inanami","year":"1988","journal-title":"Neurosci Lett"},{"key":"2021122704521290200_R37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.brainres.2006.10.047","article-title":"An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro","volume":"1128","author":"Veronesi","year":"2007","journal-title":"Brain Res"},{"key":"2021122704521290200_R38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-510X(92)90144-A","article-title":"TRH analogue, TA-0910 (3-methyl-(s)-5,6-dihydroorotyl-L-histidyl-L-prolinamide) enhances neurite outgrowth in rat embryo ventral spinal cord in vitro","volume":"112","author":"Iwasaki","year":"1992","journal-title":"J Neurol Sci"},{"key":"2021122704521290200_R39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4014\/jmb.1012.12003","article-title":"Protective effect of cyclo(his-pro) on streptozotocin-induced cytotoxicity and apoptosis in vitro","volume":"21","author":"Koo","year":"2011","journal-title":"J Microbiol Biotechnol"},{"key":"2021122704521290200_R40","doi-asserted-by":"crossref","first-page":"32281","DOI":"10.1074\/jbc.273.48.32281","article-title":"Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor","volume":"273","author":"Cao","year":"1998","journal-title":"J Biol Chem"},{"key":"2021122704521290200_R41","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/2\/152\/41866619\/stcltm_5_2_152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/2\/152\/41866619\/stcltm_5_2_152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:49:39Z","timestamp":1642560579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/5\/2\/152-163\/6397832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,18]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,12,18]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2015-0059","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,2,1]]},"published":{"date-parts":[[2015,12,18]]}}}